Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ZN-e4 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Phase 1 | EXPERIMENTAL | Up to 9 sequential dose escalation cohorts to determine maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is identified. |
| Phase 2 | EXPERIMENTAL | MTD/RP2D in subjects: Cohort 1: with T790M mutation in epidermal growth factor receptor (EGFR) gene, and are osimertinib naïve. Cohort 2: EGFRm amenable to EGFR inhibitor therapy (eg, exon 19 del, L858R) and who have never been treated with EGFRis. |
| Name | Type | Description |
|---|---|---|
| ZN-e4 | DRUG | Oral dose, tablet, daily dosing |
INCLUSION CRITERIA * Age ≥ 18 years * Histologically or cytologically confirmed metastatic or advanced inoperable diagnosis of NSCLC * Documented radiographic progression on the last treatment administered prior to enrolling in the study. * Phase 1 only: Confirmation that the tumor harbors an EGFR ...
ZN-e4 is an investigational small molecule being studied for the treatment of carcinoma, non-small-cell lung cancer. It is being developed by Zentalis Pharmaceuticals, Inc. (ticker: ZNTL) and is currently in Phase 1 clinical development.
ZN-e4 is being studied in patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer, indicating it targets the EGFR pathway. It is a small molecule therapeutic being developed by Zentalis Pharmaceuticals, Inc. for this oncology indication.
ZN-e4 is being developed by Zentalis Pharmaceuticals, Inc., a biopharmaceutical company traded on the stock exchange under the ticker ZNTL. The drug is an investigational small molecule intended for the treatment of non-small cell lung cancer.
ZN-e4 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. A Phase 1 study of ZN-e4 in subjects with EGFR-mutated non-small cell lung cancer has been completed.
ZN-e4 has been studied in one clinical trial, identified as NCT03446417, titled 'A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer'. This Phase 1 trial enrolled 34 participants and has been completed.
ZN-e4 is the investigational name for the drug being developed by Zentalis Pharmaceuticals, Inc. No alternative names for ZN-e4 have been disclosed in the available clinical trial information.